Aprea's myeloid program iced by FDA while tricky adverse event profile is sorted out

Byline: Annalee Armstrong The FDA slapped a hold (https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-partial-clinical-hold-myeloid) on Aprea Therapeutics' myeloid malignancy programs for eprenetapopt after serious side effects cropped up in trial patients. But the high-risk nature [...]